within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FB01_InotuzumabOzogamicin;

model InotuzumabOzogamicin
  extends Pharmacolibrary.Drugs.ATC.L.L01FB01;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01FB01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Inotuzumab ozogamicin is an anti-CD22 monoclonal antibody-drug conjugate used in the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). It is approved for medical use and works by delivering a cytotoxic agent directly to cancerous B-cells expressing CD22.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were reported from clinical studies in adult patients with relapsed or refractory B-cell precursor ALL following intravenous administration.</p><h4>References</h4><ol><li><p>Advani, A, et al., &amp; Fayad, L (2010). Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin&#x27;s lymphoma: results of a phase I study. <i>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</i> 28(12) 2085–2093. DOI:<a href=&quot;https://doi.org/10.1200/JCO.2009.25.1900&quot;>10.1200/JCO.2009.25.1900</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20308665/&quot;>https://pubmed.ncbi.nlm.nih.gov/20308665</a></p></li><li><p>Kantarjian, H, et al., &amp; O&#x27;Brien, S (2013). Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. <i>Cancer</i> 119(15) 2728–2736. DOI:<a href=&quot;https://doi.org/10.1002/cncr.28136&quot;>10.1002/cncr.28136</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23633004/&quot;>https://pubmed.ncbi.nlm.nih.gov/23633004</a></p></li><li><p>Ogura, M, et al., &amp; Ohata, J (2010). Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. <i>Cancer science</i> 101(8) 1840–1845. DOI:<a href=&quot;https://doi.org/10.1111/j.1349-7006.2010.01601.x&quot;>10.1111/j.1349-7006.2010.01601.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20491780/&quot;>https://pubmed.ncbi.nlm.nih.gov/20491780</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end InotuzumabOzogamicin;
